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Abstract
The capacity to generate myriad differentiated cell types, including neurons, from human
embryonic stem cell (hESC) lines offers great potential for developing cell-based therapies and
also for increasing our understanding of human developmental mechanisms. In addition, the
emerging development of this technology as an experimental tool represents a potential
opportunity for neuroscientists interested in mechanisms of neuroprotection and
neurodegeneration. Potentially unlimited generation of well-defined functional neurons from hES
and patient specific induced pluripotent (iPS) cells offers new systems to study disease
mechanisms, signalling pathways and receptor pharmacology within a human cellular
environment. Such systems may help in overcoming interspecies differences. Far from replacing
rodent in vivo and primary culture systems, hES and iPS cell-derived neurons offer a
complementary resource to overcome issues of interspecies differences, accelerate drug discovery,
study of disease mechanism as well as provide basic insight into human neuronal physiology.
Introduction
Model organisms such as rodents have contributed greatly to our understanding of how the
CNS functions in health and disease. Through the use of whole animal experiments and the
study of ex vivo preparations and cultures of primary neurons and glial cells, detailed
mechanisms of how neurons function and respond to environmental and traumatic stimuli
have been elucidated. These findings are translatable to the human condition, given the
conservation of gene orthologs and neuronal organisation, and also of CNS structure and
development. Insights gained from rodent studies have revealed new therapeutic targets and
treatment strategies in many diseases, including those afflicting the CNS. Despite this, there
remains room for improved or complementary experimental models in which to study
human disease mechanisms or cytoprotective strategies.
Human embryonic stem cells (hESCs) are pluripotent cell lines derived from the inner cell
mass of the blastocyst. They are karyotypically normal and are capable of unlimited
proliferation in their pluripotent state (1). HESCs can be readily neuralised generating neural
stem cells (NSCs) and their functional derivatives including neurons (2, 3). A key advantage
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of hESC derived NSCs (hESC-NSCs) over alternative sources of human NSCs are that
hESC-NSCs retain developmental competence to patterning signals and thus can be directed
to regional neuronal subtypes. Critically, cells specified this way in vitro retain their
imposed positional identity and differentiate appropriately when transplanted in vivo. This
ability to reliably generate scaleable and enriched numbers of functional human neurons
offers a tremendous experimental opportunity to study mechanisms of neurotoxicity and
neuroprotection (4).
Generation of regionally specified neurons from hESCs as an experimental
resource
The ability to direct neuroectodermal differentiation from hESCs has progressed rapidly in
the last decade and reflects the near “default” nature of neural induction from ESCs when
grown in conditions with limited extrinsic signalling. The most widely applied neuralising
systems employ spontaneous differentiation with subsequent growth factor mediated
propagation of neural precursors. Refinements include addition of retinoic acid to hESC
aggregates, antagonism of the nodal / SMAD signalling pathway or co-culture with stromal
cells and conditioned media (1, 5-7). Resulting hES-derived neural precursors can be
propagated and expanded long-term (over 150 days) in adherent or substrate free conditions
under defined conditions supplemented with mitogens such as EGF/FGF2 (8, 9). Subsequent
differentiation of neural precursors upon plating onto substrate and withdrawal of mitogens
confirms neuronal and glial potential. Importantly, hES-NSCs display a temporal
determination of differentiation, consistent with neural development, with neurogenesis
preceding gliogenesis. Early precursors thus represent an attractive population from which
to generate region specific neurons through application of developmentally based signals.
Neurons generated from hESCs under chemically defined conditions in the absence of
exogenous morphogens including retinoic acid tend to differentiate towards an anterior
positional identity (10) as has been found for mouse hESCs (11). However, the use of
morphogens or the activation/inhibition of key developmental pathways enables functional
neurons of different positional identities to be created. For example, we recently showed that
inhibition of activin/nodal signaling results in hESC-NPCs of a strongly posterior/spinal
cord positional identity to be generated (12). Classical anterior NPC markers such as PAX6
and OTX2 are suppressed while posterior markers such as HOXC8 and HOXB6 are up-
regulated. These neurons fire TTX-sensitive action potentials and express functional AMPA
receptors and NMDARs as assessed electrophysiologically and by Ca2+ imaging (12).
Moreover they exhibit TTX-sensitive spontaneous excitatory postsynaptic currents and
TTX-insensitive miniature EPSCs which were blocked by the AMPAR antagonist CNQX,
confirming presence of synaptic AMPA receptors. Furthermore, these neurons are sensitive
to both peroxide and glutamate-induced death (Fig. 1).
Other laboratories have created specific neuronal types with markers consistent with
midbrain dopamingergic neurons, spinal motor neurons and striatal neurons (3, 13-16).
Recognising that all such populations although enriched, remain heterogeneous, there is a
need for additional selection methods to further purify neuronal sub-type lineages. Sub-type
specific reporter lines are one such method. While a key aim of positionally specifying
hESC-NPCs is to work towards the generation of cell-based therapies for diseases that target
a sub-population of cells, they will also provide a valuable resource for research into those
very same diseases, (4). Future application of regional specification will be particularly
powerful in attempting to understand disease specificty when applied to induced disease-
specific pluripotent stem cells (iPS cells). The emergence of iPS cells, through manipulation
of somatic cells by overexpression of key transcription factors to generate embryonic stem
(ES) like cells, offers additional experimental and therapeutic possibilities. Combining
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somatic cell reprogramming technology to generate patient specific iPS cell lines carrying
disease-causing mutations, with neural developmental insights offers the unique opportunity
to develop bespoke human in vitro models of disease. Indeed, recent studies have confirmed
the utility of such an approach with resulting neuronal cells displaying a disease phenotype
as well as being an unique assay for drug discovery and testing (17, 18). Neural precusors
were generated from an iPS cell line developed from fibroblasts taken from a spinal
muscular atrophy patient, a disease characterised by selective loss of lower motor neurons
caused by mutation in the survival motor neuron 1 gene (SMN1) gene. Compared to a wild-
type iPS cell line, SMA-iPS cells were equally amenable to differentiation into immature
motor neurons, but numbers of motor neurons observed at later timepoints post-
differentiation were much lower in the SMA-iPS cell cultures, compared to wild-type,
indicative of either impaired production or selective degeneration of motor neurons (17). In
another recent example, iPS cells were generated from a patient with familial dysautonomia
(FD), a fatal peripheral neuropathy, caused by a point mutation in the IKBKAP gene leading
to depletion of autonomic and sensory neurons. FD-iPS cell-derived neural precursors have
particularly low levels of IKBKAP, mis-splicing of IKBKAP, and defects in neurogenic
differentiation and migration behaviour (18). Together these studies demonstrate that in
vitro developmentally based human neuronal culture systems can reproduce a phenotype
normally observed in vivo in juvenile or adult life.
Species-specific differences in signaling and gene expression indicate a
role for studying human neurons
Despite the relevance of rodent models to the human condition, there are differences
between rodent and human cellular systems that have the potential to cloud the inferences
we can take from rodent studies. These differences should not be overstated, but
nevertheless point to the benefit of having hESC-derived neurons as an additional tool for
probing toxic and protective signaling pathways, validating therapeutic targets, and aiding
drug discovery (19). Important interspecies differences are also evident in the signalling
requirements underlying pluripotency of mouse and human ES cultures. Specifically mouse
ES cells require activation of the JAK/STAT pathway through LIF whereas there is no
requirement of LIF for human ES cell maintenance. Human ES cells are dependent on
activin/nodal and FGF signalling. As outlined below, interspecies differences in
transcriptional responses represent a potential point of difference. However, anecdotal
differences in many aspects of cell biology have been reported, leading one to speculate that
other unknown differences await detection.
Evolutionary turnover of transcription factor binding sites
Endogenous neuroprotective pathways, such as those triggered by synaptic NMDA receptor
activity, or neurotrophic factors, exert their effect in part via changes in gene expression (20,
21). Through the up-regulation of pro-survival genes and the suppression of pro-death
genes, the affected neurons can gain resistance to subsequent insults. Other less
advantageous effects, such as those of disease-causing agents, or harmful side-effects of
drugs can rely significantly on effects on intracellular signalling pathways causing changes
in gene expression. Whilst many key factors mediating these processes are likely to be
conserved in rodent and human systems, there may be some differences. At the
transcriptional regulation level there is evidence for turnover of transcriptional regulatory
elements. A significant fraction of functional human transcription factor binding sites are not
functional in rodents (22). A more recent study on a number of functionally conserved
tissue-specific transcription factors in mouse and human primary hepatocytes showed that
the conservation of transcription factor occupancy in orthologous mouse and human gene
promoters could be highly variable (23). Interestingly, while interspecies differences in
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binding events were very large, the location of binding events within two different human
systems: primary human hepatocytes and a human hepatocarcinoma cell line HepG2, was
highly conserved (23). These observations all strengthen the case for employing hESC-
derived neurons to study transcriptional responses alongside rodent neurons in order to
identify interspecies differences and thus home in on the most human-relevant pathways that
could (for example) be explored further in rodent in vivo models.
There are many potential reasons why transcription factor binding events may not be
conserved between species, such as non-equivalent developmental stages, or interspecies
differences in transcription factor expression levels or even specificity. However, gene
promoter sequence, as opposed to any differences in transcriptional machinery appears to be
the dominant factor directing species-specific transcription (24). One recent study involved
analysis of transcription factor binding events and the resulting gene expression associated
with human chromosome 21 when carried by an aneuploid mouse strain (24). Study of
hepatocytes from these mice compared to human ones revealed that human-specific binding
and expression patterns were recapitulated in the mouse cells. Thus, genetic sequence is the
primary determinant of the transcriptional response, rather than cellular environment.
Collectively, these findings have implications for trying to predict the transcriptional
response in a human cell to a particular stimulus by studying the response in a rodent cell. In
an example directly relevant to our research, we recently identified a gene, sulfiredoxin that
is regulated by synaptic NMDAR activity in rat neurons via two AP-1 sites (25). The
induction of this gene contributed to the enhanced antioxidant defenses found in electrically
active rat neurons. However, one of these sites has been lost in the primate lineage, despite
being well conserved among other mammals. While the loss of this site may have only a
small effect on the inducibility of sulfiredoxin in human neurons, it would certainly be of
importance to study the activity-dependent induction of this gene in hESC-derived forebrain
neurons.
Other potential sources of interspecies differences
Post-transcriptionally, species-specific differences in the intron/exon pattern of genes and of
alternative splicing patterns can lead to the products of conserved genes becoming
functionally different (26, 27). There are species-specific differences in the expression and
distribution of different isoforms of the human and mouse Tau genes (MAPT) (28). Species-
specific differences in splicing of the Na+/Ca2+ transporter 1 (NCX1) gene have been
reported (29). The NCX genes are important for neuronal Ca2+ homeostasis, particularly
when substantial Ca2+ influx takes place, for example following an excitotoxic insult.
Indeed, calpain-mediated cleavage and inactivation of the NCX3 gene contributes to the
delayed Ca2+ deregulation and subsequent neuronal death (30) although there is no evidence
of interspecies differences in its processing.
Post-translationally, protein-protein interactions can also vary, as can the distribution of
gene products and the substrate profile of an enzyme. For example, while the C-terminal
PDZ ligand of the human somatostatin receptor 3 interacts with the PDZ protein MUPP1,
the corresponding ligand of the rat receptor does not (31). PDZ ligand interactions are
important in the organization of neuron-specific macromolecular complexes such as the
NMDA receptor signaling complex (32, 33). Coupling of the NMDA receptor NR2 subunit
to toxic nitric oxide production and activation of pro-death p38 signaling is mediated by
PDZ domains on PSD95 and neuronal nitric oxide synthase, and a PDZ ligand on NR2
(34-36) (though this is completely conserved between rodents and humans).
The activation of caspases is central to the initiation and execution of apoptosis (37).
Apoptotic-like neuronal death or the activation of apoptotic biochemical cascades (e.g.
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caspases) are proposed to be associated with certain neurodegenerative diseases, such as
Alzheimer’s and Parkinson’s Disease (38-41) where they are implicated both in neuronal
death and also proximal events such as cleavage of amyloid precursor peptide and tau (41).
As would be expected for a cellular mechanism as important as apoptosis, this is highly
conserved within mammals. Nevertheless there do exist species-specific (human vs. mouse)
differences in they way caspases process their targets, and even in whether a protein is a
caspase target at all (42).
Of direct importance to therapeutics is the fact that some pharmacological compounds show
large species-specific differences. Specific differences between rodent and human channel/
receptor pharmacology are documented in cases such as the P2X receptor (43) the TRPV1
channel (44) and the TRPA1 receptor (45). The potential for species-specific differences
motivates studies employing the human receptor expressed ectopically in a heterologous
system, such as a recent study on the effect of the NMDA receptor antagonist memantine on
human NR2A-containing NMDARs expressed in HEK293 cells (46). While worthwhile,
such approaches can only study a single recombinant receptor, while native receptors may
have varying subunit compositions and may be associated with post-translational
modification and/or accessory proteins that alter the pharmacology of certain compounds.
Conclusions
While hESC-derived neurons are unlikely to replace any of the established experimental
systems for studying neurotoxicity and neuroprotection, they have a valuable
complementary role to play, and may reduce the overall use of animals in research. The
experimental testing of a hypothesis in rodent in vitro and in vivo systems and also in hESC-
derived neurons increases the burden of proof that a particular mechanism is relevant to the
human organism, since each system has different limitations. Other in vitro uses for hESC-
derived neurons include analysing the effects of neuroprotective receptor agonists/
antagonists on native human receptors in a human cellular environment. The scalable nature
of hESC systems means that hESC-derived neurons have the potential to be used in
screening assays, potentially aiding drug discovery for neuroprotective compounds (19). The
functional characterisation of hESC-derived neurons is developing exponentially, as are
protocols for generating increasingly well defined region- or phenotype-specific neuronal
populations. Aside from their much-vaunted potential for cell-based therapies, hESC-
derived neurons have the potential to become an important tool for molecular
neuroscientists.
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Fig. 1.
Neurons derived from hESCs as described (12) were treated for 8 h with glutamate (200
μM) or H2O2 (200 μM). Pictures before/after exposure were taken. Both insults led to
nuclear pyknosis that was preceded by neuritic beading. Scale bar 50 μm.
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